Advertisement

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Stefan H, Snead OC III (1997). Absence seizures. In: Engel J Jr, Peadley T (eds) Epilepsy. A comprehensive textbook. Lippincott Raven Publishers, Philadelphia, 579590.Google Scholar

Literatur

  1. 1.
    Commission on Classification and Terminology of the International League against Epilepsy (1989). Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389–399.Google Scholar

Literatur

  1. 1.
    Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327:1769–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface protein lipoprotein A with adjuvant. N Engl J Med 1998;339:209–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Strie F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999; 111: 911–915Google Scholar

Literatur

  1. 1.
    Harding A.E (1982). The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the Drew family of Walworth’. Brain, 105(Pt 1):1–28.PubMedGoogle Scholar
  2. 2.
    Klockgether T, Bürk T and Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B und Ceballos-Baumann A.O. (Hrsg.) Bewegungsstörungen in der Neurologie, Thieme, Stuttgart New York 254–279.Google Scholar
  3. 3.
    Tan E.-K. and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58: 191–195.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120:1485–1508.PubMedCrossRefGoogle Scholar
  2. 2.
    Singh I et al. (1998) Lovastatin for X-linked adrenoleukodystrophy. NEJM 339:702–703.PubMedGoogle Scholar

Literatur

  1. 1.
    Curran HV et al. (1994) Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agarophobia with panic disorder. Psychol Med 24:969–976.PubMedCrossRefGoogle Scholar
  2. 2.
    Mavissakalian MR and Ryan MT (1998) Rational Treatment of Panic Disorder with Antidepressants. Ann Clin Psych 10:185–195.Google Scholar
  3. 3.
    Van Balkom A et al. (1997) A Meta-Analysis of the Treatment of Panic Disorders with or without Agoraphobia: A Comparison of Psychopharmacological, Cognitive-Behavioral and Combination Treatment. J Neur Ment Dis 185:510–516.Google Scholar

Literatur

  1. 1.
    Baxter PS et al. (1995) Vigabatrin monotherapy in resistant neonatal seizures. Seizure 4(1):57–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Talens C et al. (1987) Early stimulation: psychomotor development of two girls with Aicardi syndrome. Child Care Health Dev 13(2):101–9.PubMedGoogle Scholar

Literatur

  1. 1.
    Feasby TE, Gilbert JJ, Brown WF, et al. (1986) An acute axonal form of Guillain-Barré polyneuropathy. Brain 109:1115–1126.PubMedGoogle Scholar
  2. 2.
    Flachenecker P, Reiners K (1999). Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences 165:144–153.Google Scholar
  3. 3.
    Flachenecker P, Toyka KV, Reiners K (2001). Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt 72:610–617.PubMedCrossRefGoogle Scholar
  4. 4.
    Hadden RDM, Cornblath DR, Hughes RAC, et al. (1998) The Plasma exchange/Sandoglobin Guillain-Barre Syndrome Trial Group. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 44:780–788.PubMedCrossRefGoogle Scholar
  5. 5.
    Hartung HP, Willison HJ, Kieseier BC (2002). Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. Curr Opin Neurol 15 (5):571–577.PubMedCrossRefGoogle Scholar
  6. 6.
    Hughes RAC, Swan AV, Cornblath DR, et al. (1997) Randomised trials of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349:225–230.Google Scholar
  7. 7.
    Rees JH, Soudain SE, Gregson NA, Hughes RAC (1995). Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 23:1374–1379.Google Scholar
  8. 8.
    The Dutch Guillain-Barré Study Group (1994). Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann Neurol 35:749–752.Google Scholar
  9. 9.
    The Guillain-Barré Study Group (1985). Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104.Google Scholar
  10. 10.
    van der Meche FG, Schmitz PI and the Dutch Guillain-Barré Study Group (1992). A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barrésyndrome. N Engl J Med 326:1123–1129.PubMedGoogle Scholar

Literatur

  1. 1.
    Flachenecker P, Reiners K (1999). Twenty-fourhour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barre syndrome. J Neurol Sciences,165:144–153.CrossRefGoogle Scholar
  2. 2.
    Flachenecker P, Toyka KV, Reiners K (2001). Herzrhythmusstörungen beim Guillain-Barre-Syndrom. Nervenarzt 72:610–617.PubMedCrossRefGoogle Scholar
  3. 3.
    Flachenecker P, Wermuth P, Hartung H-P, Reiners K (1997). Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol 42:171–179.PubMedCrossRefGoogle Scholar
  4. 4.
    Hilz MJ, Claus D, Bauer J, Neundörfer B (1990). Transcutaneous cardiac pacemaker for prevention and emergency therapy in neurologic intensive care patients. Nervenarzt 61(12):744–748.PubMedGoogle Scholar
  5. 5.
    Pfeiffer G, Schiller B, Kruse J, Netzer J (1999). Indicators of dysautonomia in severe Guillain Barre syndrome. J Neurol. 246:1015–1022.PubMedCrossRefGoogle Scholar
  6. 6.
    Winer JB, Hughes RAC (1988). Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Q J Med 257:735–739.Google Scholar

Literatur

  1. 1.
    Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A (2000). Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software.Google Scholar
  2. 2.
    Rutherford GW, Feldman KA, Kennedy, GE (2000). Three-or four-versus two-drug antiretroviral maintenance regimens for HIV infection (Cochrane Review). The Cochrane Library, Issue 2, Oxford Update Software.Google Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar
  2. 2.
    IONDT-group (ischemic optic neuropathy decompression trial search group) (1995) Optic nerve decompression surgery for NAION is not effective and may be harmful. JAMA 273: 625–632.Google Scholar

Literatur

  1. 1.
    Lumenta CB, Brückmann H, Feldmann HJ, Strupp ML, Wowra B (2001). Neurinome. In: Tumorzentrum München (Hrsg.) Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Zuckschwerdt, München Bern Wien New York.Google Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Bou J, Domenech T, Puig J et al. (2000) Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 410:33–41PubMedCrossRefGoogle Scholar
  2. 2.
    Bou J, Domenech T, Gras J et al. (1997) Pharmacological profile of almotriptan, a novel antimigraine drug. Cephalalgia 17:421–422Google Scholar
  3. 3.
    Gras J, Bou J, Llenas J et al. (2000) Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 410:43–51PubMedGoogle Scholar
  4. 4.
    Fernandez FJ, Cabarrocas X, Zayas JM et al. for and on behalf of the Almotriptan Dose Finding Study Group (1999) Oral almotriptan in the treatment of migraine. Cephalalgia 19:362–362Google Scholar
  5. 5.
    Pascual J (2000) Therapy with other triptans: almotriptan. In: Diener HC (Hrsg.) Drug treatment of migraine and other headaches. Karger, Basel, S. 197–205Google Scholar
  6. 6.
    Pascual J, Falk RM, Piessens F et al. (2000) Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, doubleblind, placebo-controlled study. Cephalalgia 20:588–596PubMedGoogle Scholar
  7. 7.
    Cabarrocas X, Zayas JM, on behalf of the almotriptan Oral Study Group (1998) Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache 38:377–378Google Scholar
  8. 8.
    Cabarrocas X, Zayas JM, for and on behalf of the Almotriptan Comparative Study Group (1999) Advantageous tolerability of almotriptan 12,5 mg compared with sumatriptan 100 mg. Headache 39:347Google Scholar
  9. 9.
    Martinez E, Cabarrocas X, Peris F et al. (1999) Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 19:362Google Scholar
  10. 10.
    Pascual J, Falk RM, Docekal P et al. (2001) The tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 45 (4)Google Scholar
  11. 11.
    Almirall Prodesfarma, Bayer Vital GmbH 12,5 mg Filmtablette (2000) Fachinformation November 2000Google Scholar
  12. 12.
    Matthew NT (2000) Results of a 1-year open study on almotriptan. London, Headache World (abstract)Google Scholar

Literatur

  1. 1.
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V for the Amyotrophic Lateral Sclerosis / Riluzole Study Group-II (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431.PubMedGoogle Scholar

Literatur

  1. 1.
    Aisen et al. (2000) A randomized trial of prednisone in Alzheimer’s disease. Neurology 54(3): 588–593.PubMedGoogle Scholar
  2. 2.
    Alastair J.J., Wood M.D (1999). Treatment of Alzheimer’s Disease. The New England Journal of Medicine 341:1670–1679.Google Scholar
  3. 3.
    Henderson et al. (2000) Estrogen for Alzheimer’s disease in women. Randomized, double-blind, placebo-controlled trial. Neurology 54:295–301.PubMedGoogle Scholar
  4. 4.
    In’t Veld BA, Ruitenberg A, Stricker BH et al. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521.Google Scholar
  5. 5.
    Knapp MJ, Knopmann DS, Soloman PR, Pendlebury WW, Davis CS, Gracon SI. A (1994). 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’disease. JAMA 271:985–991.PubMedCrossRefGoogle Scholar
  6. 6.
    Le Bars PL, Katz MM, Berman N, Itil TM, Freedmann AM, Schatzberg AF (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginko biloba for dementia. JAMA 278:1327–1332.PubMedGoogle Scholar
  7. 7.
    Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group Neurology. Jun 27; 54(12):2261–8.Google Scholar
  8. 8.
    Rösler M, Anand R, Cicin-Sain A, et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’disease: international randomized controlled trial. BMJ 318:633–638.PubMedGoogle Scholar
  9. 9.
    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998). Donepezil study group. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimers’ disease. Neurology 50:136–145.PubMedGoogle Scholar
  10. 10.
    Sano M, Ernesto C, Thomas RG et al. (1997) A controlled trial of selegeline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336:1216–1222.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Kain Z et al. (2000) Midazolam: effects on amnesia and anxiety in children. Anesthesiology 93:676–84.PubMedGoogle Scholar
  2. 2.
    Verwey B et al. (2000) Memory impairment in those who attempted suicide by benzodiazepine overdose. J Clin Psychiatry 61:456–9.PubMedGoogle Scholar

Literatur

  1. 1.
    Mrazek M et al. (1999) Therapeutische Erfahrungen beim alkoholbedingten Korsakow-Syndrom. Nervenarzt 70:790–794.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Rösler A et al. (1999) Precipitating factors of transient global amnesia. J Neurol 246:53–54.).PubMedGoogle Scholar
  2. 2.
    Berlit P (2000) Successful prophylaxis of recurrent transient global amnesia with metoprolol. Neurology 55:1937–1938.PubMedGoogle Scholar
  3. 3.
    Zeman AZJ & Hodges JR (1997). Transient global amnesia. Br J Hosp Med 58:257–260.PubMedGoogle Scholar

Literatur

  1. 1.
    Zeman AZ, Boniface SJ, Hodges JR (1998). Transient epileptic amnesia: A description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry 4:435–443.Google Scholar

Literatur

  1. 1.
    Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN (1998) Allogenic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 100: 226–228.PubMedCrossRefGoogle Scholar
  2. 2.
    Kyle RA, Dyck PJ (1993) Amyloidosis and neuropathy. In: Dyck PJ, Thomas PK (Hrsg) Peripheral neuropathy. WB Saunders Company, Philadelphia, pp 1294–1309.Google Scholar
  3. 3.
    Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336: 1202–1207.PubMedCrossRefGoogle Scholar
  4. 4.
    Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation Amyloidose, in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101:766–769.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    ISUIA Investigators (1998) Unruptured intracranial aneurysms — risk of rupture and risks of surgical intervention. The New England Journal of Medicine 24:1725–1733.Google Scholar
  2. 2.
    Brilstra et al. (1999) Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke 30(2):470–476.PubMedGoogle Scholar
  3. 3.
    Bederson et al. (2000) Recommendations for the management of patients with unruptured intracranial aneurysma. Stroke 31:2742–2750.PubMedGoogle Scholar

Literatur

  1. 1.
    Brilstra et al. (1999) Treatment of intracranial aneurysms by embolization with coil: a systematic review. Stroke 30(2):470–476. International Subarachnoid Aneurysm Trial (ISAT)PubMedGoogle Scholar
  2. 2.
    ISAT (International Subarachnoid Aneurysm Trial) Lancet 2002; 360:1267–1274Google Scholar

Literatur

  1. 1.
    Commission on Classification and Terminology of the International League against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.Google Scholar

Literatur

  1. 1.
    Commission on Classification and Terminology of the International League against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.Google Scholar

Literatur

  1. 1.
    Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO (2000). Infusion of alpha-galactosidase A reduces tissue globotriao-sylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365–370.PubMedCrossRefGoogle Scholar
  2. 2.
    Abe A, Arend LJ, Lee L, Lingwood C, Brady RO, Shayman JA (2000). Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int 57:446–454.PubMedGoogle Scholar

Literatur

  1. 1.
    Krämer, G (1999). Epilepsien im höheren Lebensalter. Thieme, Stuttgart, New York.Google Scholar
  2. 2.
    Stefan H (1999). Epilepsien: Diagnose und Behandlung. Thieme, Stuttgart, New York.Google Scholar

Literatur

  1. 1.
    Tunick PA et al. (2002) Am J Cardiol 90:1320–25.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Penkert G, Carvalho GA, Nikkhah G, Tatagiba M, Matthies C, Samii M (1999) Diagnosis and surgery of brachial plexus injuries. J Reconstr Microsurg 15: 3–8.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Berlit P (1992) Clinical and laboratory findings with giant cell arteriitis. J Neurol Sci III, 1–12Google Scholar

Literatur

  1. 1.
    Kleihues P, Cavenee W (Hrsg.) (2000). Tumors of the Nervous System. WHO Classification of Tumours. IARC Press, Lyon.Google Scholar
  2. 2.
    Schlegel U, Westpahl M (Hrsg.) (1998). Neuroonkologie. Thieme, Stuttgart New York.Google Scholar
  3. 3.
    Walker MD, Green SB, Byar DP et al. (1980) Randomized comparisons of radiotherapy and nitrosureas for the treatment of malinant gliomas after surgery. New Engl J Med 303:1323–1329.PubMedGoogle Scholar
  4. 4.
    Shaw EG, Scheithauer BW, O’Fallon JR (1997). Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 31:273–278.PubMedCrossRefGoogle Scholar
  5. 5.
    Peraud A, Kreth FW, Siefert A et al. (2001) Niedermaligne Gliome. In: Tumorzentrum München (Hrsg.) Hirntumoren und primäre Tumoren des Rückenmarks. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Zuckschwerdt, München Bern Wien New York.Google Scholar
  6. 6.
    Albert FK, Forsting M, Sartor K et al. (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–60.PubMedGoogle Scholar
  7. 7.
    Levin VA, Silver P, Hannigan J et al. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Rad Oncol Biol Phys 18:321–324.Google Scholar
  8. 8.
    Hildebrandt J, Sahmoud T, Mignolet F et al. (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44:1479–1483.Google Scholar
  9. 9.
    Thomas DGT, Bleehan NM, Roberts JT et al. (1998) MRC randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BR05. J Neuro Oncol 39:102.Google Scholar
  10. 10.
    Yung WK, Prados MD, Yaya-Tur R et al. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–71.PubMedGoogle Scholar

Literatur

  1. 1.
    Klockgether T, Bürck T, Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B und Ceballos-Baumann A.O. (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York 254–279.Google Scholar
  2. 2.
    Tan E.-K. and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58:191–195.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Klockgether T, Bürk T und Dichgans J (1996). Zerebelläre Bewegungsstörungen (Ataxien). In: Conrad B and Ceballos-Baumann AO (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart New York 254–279.Google Scholar
  2. 2.
    Tan EK and Ashizawa T (2001). Genetic testing in spinocerebellar ataxias. Arch Neurol 58: 191–195.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Huber A, Kömpf D (1998) Klinische Neuroophthalmologie. Thieme, Stuttgart New York.Google Scholar

Literatur

  1. 1.
    Confavreux C, Saddier P, Grimaud J. et al. (1996) Risk of cancer from azathioprine therapy in multiple sclerosis. A. case-control study. Neurology 46:1607–1612.PubMedGoogle Scholar
  2. 2.
    MS-Therapie Konsensus Gruppe (MSTKG), (1999). Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt 70:371–386.Google Scholar
  3. 3.
    MS-Therapie Konsensus Gruppe (MSTKG), (2001). Immunmodulatorische Stufentherapie der Multiplen Sklerose. I. Ergänzung Dezember 2000. Nervenarzt 72:150–157.Google Scholar
  4. 4.
    Pette M (1999). Immunsuppressive, immunmodulatorische Therapie. In: Zettl UK, Mix E (Hrsg.) Klinische Neuroimmunlogie, Verlag de Gruyter, Berlin-New York. S. 261–276.Google Scholar
  5. 5.
    Tolkoff-Rubin NE, Rubin RH (1996). The purin antagonists: Azathioprine and mycophenolat mofetil. In: KF Austen, SJ Burakoff, FS Rosen et al. (Hrsg.) Therapeutic Immunology. Blachwell sciences, Cambridge. S. 44–56.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations